In terms of private investments, 2020 was the year of the liquid biopsy.
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
With funding in place, Syros is pushing its lead leukaemia project into pivotal development, and has a newly acquired second asset not far behind.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.